Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Pediatric Endocrinology

Hydrocortisone Oral Granules Approved for Pediatric Adrenocortical Insufficiency

Brian Park, PharmD

December 1, 2020

Alkindi Sprinkle contains immediate-release oral hydrocortisone granules designed for the dosing needs of pediatric patients with adrenocortical insufficiency.

Cardiovascular and Metabolic Disorders

Semaglutide Increases Weight Loss When Added to Behavioral Therapy

Brian Park, PharmD

November 12, 2020

The 68-week STEP 3 trial compared the efficacy and safety of semaglutide, a glucagon-like peptide 1 receptor agonist, to placebo plus IBT.

Diabetes

Finerenone NDA Submitted for Diabetic Kidney Disease

Brian Park, PharmD

November 12, 2020

The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.

Thyroid

Generic Version of Tirosint Now Available

Brian Park, PharmD

November 10, 2020

Levothyroxine sodium is indicated for the treatment of hypothyroidism.

Diabetes

Teplizumab BLA for Tyoe 1 Diabetes Prevention Submitted

Brian Park, PharmD

November 5, 2020

The BLA is supported by data from a phase 2 trial that evaluated whether teplizumab could prevent or delay the onset of T1D in at-risk individuals.

Thyroid

Thyroid Medication Recalled Due to Subpotent Tablets

Brian Park, PharmD

September 24, 2020

Testing revealed that the product may have as low as 87% of the labeled amount of levothyroxine.

Cardiovascular and Metabolic Disorders

Empagliflozin Fast Tracked for Improving Outcomes Following Myocardial Infarction

Brian Park, PharmD

September 22, 2020

The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.

General Endocrinology

FDA Approves Radioactive Diagnostic Agent for Neuroendocrine Tumors

Brian Park, PharmD

September 15, 2020

Detectnet (copper Cu 64 dotatate) is indicated for use with PET for localization of somatostatin receptor positive neuroendocrine tumors.

Type 2 Diabetes

Additional Doses of Dulaglutide Approved for Type 2 Diabetes

Brian Park, PharmD

September 11, 2020

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial.

Cardiovascular and Metabolic Disorders

Evolocumab Reduces LDL-C in Pediatric Heterozygous FH

Brian Park, PharmD

September 8, 2020

The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.

Next post in Cardiovascular and Metabolic Disorders